Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
AYTU vs CAPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
CAPR Captures Overall Composite Edge (28.0 SELL vs 48.9 HOLD), While AYTU Leads 4–2 on Growth & Valuation Pillars
CAPR Overall Winner
6-Pillar Tally: AYTU 4 – 2 CAPR
Matrix Metrics: AYTU 6 – 4 CAPR
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) captures the overall head-to-head institutional edge over AYTU BioPharma, Inc. (AYTU) on higher Unified Composite conviction (28.0/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while AYTU wins 4–2 across the 6-pillar growth and valuation breakdown. AYTU trades at $1.81 (9.2x Forward P/E, -14.4% operating margin) versus CAPR at $8.47 (78.7x Forward P/E, 0.0% operating margin).
- Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.4% operating margin) and revenue trajectory (-7.9% vs. +6.4% YoY).
- Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About AYTU vs CAPR
AYTU
AYTU BioPharma, Inc. Common Stock
$1.81
+1.69% 1D
Market Cap
$19.6M
TTM Revenue
$58M
Forward P/E
9.2x
Beta / 30D Vol
0.65β · 35% Vol
Unified Composite Score
48.9
HOLD
Tech 49.0
Fund 53.0
Flow 50.0
Mom 64.0
Weinstein Technical Phase
Markdown · Sell / avoid
CAPR
Head-to-Head Winner
Capricor Therapeutics Inc
$8.47
-11.12% 1D
Market Cap
$595.4M
TTM Revenue
$11M
Forward P/E
78.7x
Beta / 30D Vol
1.52β · 152% Vol
Unified Composite Score
28.0
SELL
Tech 50.0
Fund 37.0
Flow 68.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (AYTU 4 – 2 CAPR)
1. Valuation Multiples
AYTU
Forward P/E
9.2x
78.7x
Trailing P/E
9.2x
78.7x
PEG Ratio
N/M
0.38x
EV / Revenue
0.3x
57.8x
2. Growth & Scale
AYTU
Revenue Growth (YoY)
+6.4%
-7.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$58M
$11M
Market Cap
$19.6M
$595.4M
3. Profitability & Quality
CAPR
Gross Margin
64.0%
N/A
Operating Margin
-14.4%
0.0%
Net Profit Margin
-24.8%
0.0%
Return on Equity (ROE)
-52.5%
-100.5%
4. Balance Sheet & Cash Flow
AYTU
Cash Generation (TTM)
-$1.4M
-$146M
Cash Flow Margin
-2.4%
N/A
Net Cash / Leverage
$4.9M Net Cash
$48M Net Debt (0.44x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CAPR
Options Structure Phase
UNCLASSIFIED
CONSOLIDATION
Current IV / %ile
N/A (N/A)
637.1% (89th %ile)
Put/Call OI Skew
N/A
1.57x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markdown
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
AYTU
OpEx & R&D Intensity
78.4% of Rev ($45M)
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Drug Manufacturers - Specialty & Generic Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: AYTU (6) vs CAPR (4)| Institutional Metric | AYTU | CAPR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $19.6M | $595.4M | CAPR | |
| Trailing P/E Ratio | 9.2x | 78.7x | AYTU | |
| Forward P/E Ratio | 9.2x | 78.7x | AYTU | |
| Revenue Growth (YoY) | +6.4% | -7.9% | AYTU | |
| Operating Margin (TTM) | -14.4% | 0.0% | CAPR | |
| Net Profit Margin | -24.8% | 0.0% | CAPR | |
| Return on Equity (ROE) | -52.5% | -100.5% | AYTU | |
| 52-Week Range Position | 5% ($2–$3) | 15% ($3–$40) | CAPR | |
| Beta / 30D Volatility | 0.65β · 35% Vol | 1.52β · 152% Vol | AYTU | |
| Unified Institutional Score | 48.9 / 100 (HOLD) | 28.0 / 100 (SELL) | AYTU | |
| Trailing 12M Revenue (USD) | $58M | $11M | Scale | |
| Gross Profit Margin (TTM) | 64.0% | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | 0.38x PEG · 57.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$1.4M ($4.9M Net Cash) | -$146M ($48M Net Debt (0.44x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAPR +37.5 pp
3M Horizon
CAPR +42.94 pp
6M Horizon
AYTU +53.23 pp
1Y Horizon
CAPR +58.93 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AYTU Revenue | CAPR Revenue | AYTU Op. Margin | CAPR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -230.1% | -769.5% | AYTU |
| FY2020 | $30M | $0M | -76.5% | -4412.6% | AYTU |
| FY2021 | $70M | $0M | -89.7% | -8549.9% | AYTU |
| FY2022 | $100M | $0M | -113.7% | -1163.9% | AYTU |
| FY2023 | $110M | $30M | -15.9% | -95.6% | AYTU |
| FY2024 | $70M | $20M | -2.4% | -191.1% | AYTU |
| FY2025 | $70M | N/A | -11.8% | N/A | AYTU |
| FY2026 | $60M | N/A | -14.4% | N/A | AYTU |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
AYTU
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CAPR
CONSOLIDATION
Current IV
637.1%
IV Percentile
89th %ile
Put/Call OI Skew
1.57x (Put-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
AYTU Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
78.4% of Rev ($45M)
90D Engineering Disclosures
0 Published
CAPR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ AYTU vs CAPR Key Questions & Quantitative Answers
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) captures the overall head-to-head institutional edge over AYTU BioPharma, Inc. (AYTU) on higher Unified Composite conviction (28.0/100 SELL vs. 48.9/100 HOLD) after splitting the core matrix 4–6 (led by Profitability & Quality, Options & Positioning), while AYTU wins 4–2 across the 6-pillar growth and valuation breakdown. AYTU trades at $1.81 (9.2x Forward P/E, -14.4% operating margin) versus CAPR at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AYTU currently prints a higher short-term Unified Composite Score (48.9/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -14.4% operating margin) and revenue trajectory (-7.9% vs. +6.4% YoY). Technical & Structure Timing Caution: AYTU is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
AYTU leads the Growth & Scale pillar: AYTU posts +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), AYTU cumulative revenue shifted +500.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, AYTU deploys 78.4% of Rev ($45M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.
AYTU screens cheaper on headline valuation multiples. AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AYTU (-52.5% ROE) versus CAPR (-100.5% ROE) capital efficiency.
In options market volatility and institutional positioning, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CAPR vs AYTU · Reverse Pair
CAPR vs MBRX
· Sector Peer
CAPR vs AKTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal